The ATTACK project involves two multi-centre clinical trials to treat cancer using a form of cell therapy called Adoptive T-Cell Therapy.
project no data have been generated yet with respect to the additional research questions. In parallel, pre-clinical research has developed novel strategies for the enrichment of effective T-cell subsets and optimized their activation, gene-modi cation and expansion using newly co-developed soluble activation reagents, culture conditions (i.e. TexMACS medium + IL-7 and IL-15) and a dedicated closed single-use tubing set where all steps were integrated in a stepwise approach. We nally managed to develop a process on the CliniMACS Prodigy which integrates all essential steps for clinical-grade manufacturing of gene-modi ed T -cells. Automation of the manufacturing process is economically advantageous. This will contribute to the commercial realisation of adoptive cell transfer therapy. Moreover, user interactions and open handling steps for the T cell transduction process were reduced to a minimum to increase safety for each run making a complex procedure more reliable. Trial II: A randomised phase II trial in Melanoma to investigate an alternative cell manufacturing process with 3 potential improvements compared to the "standard method": a) Selection of CD62L+ cells with greater re-population potential, b) An alternative cell activation step (TransAct) and c) Expansion in IL-7/IL-15 to maintain a less differentiated state with greater repopulation potential. The manufacturing process was quali ed pre-clinically and was undergoing GMP validation when the project was terminated.
Unfortunately, due to the delays seen in the progress of ATTACK, the European Union has terminated funding of the ATTACK project with effect from 26th June 2016.
Project Context and Objectives: 2.1 The ATTACK Project Targeted nucleic acid delivery by genetically engineering T-cells to target tumour associated antigens expressed on malignant cells demonstrates extraordinary e cacy in pre-clinical models of advanced cancer (Klebanhoff et al., 2011) and recent results con rm the clinical effectiveness of the treatment (Morgan et al., 2006; Robbins et al., 2011; Kochenderfer et al., 2010; Porter et al., 2011) . However, the use of engineered T-cells is a challenging eld and key clinical and methodological questions remain unanswered. These include: 1. Is the approach active in common epithelial malignancies? -as current trials have focussed on melanoma and B-cell malignancies 2. The production of optimised genetically engineered T-cells is critical and the number and quality of cells can clearly in uence the outcome. The choice of the T-cell subset(s) may also be important as they can engraft to different extents.
The aim of ATTACK was to exploit technology for nucleic acid delivery through the clinical testing of adoptive transfer of engineered Tcells to treat cancer and build upon previous EU funded pre-clinical projects (FP5 Chimeric Eurocell; FP6 ATTACK; FP7 ATTRACT). The consortium, which comprises a multidisciplinary and translational research group with wide-ranging relevant expertise, were to initiate two landmark studies to (i) examine activity of engineered T-cells in oesophago-gastric cancer as an example of a hard to treat common epithelial cancer, (ii) undertake a randomised Phase II study to determine whether an optimised cell production system improved the current clinical response rates in patients with metastatic melanoma treated with NY-ESO-1 targeted T-cells.
Approach and Methodology
The work plan was composed of three principle scienti c work packages (WP1-WP3).
WP1: Clinical Trials
WP1 centred upon delivery of the two clinical trials targeting NY-ESO-1. Enrolment onto each trial required patients to be HLA-A*0201 positive and their tumour to be NY-ESO-1 and/or LAGE positive.
Trial I:
A Phase II Clinical Trial to Assess the Activity of NY-ESO-1 Targeted T-cells in Advanced Oesophago-Gastric Cancer
This trial aimed to evaluate the activity of engineered T cells to target NY-ESO-1 in oesophago-gastric cancer for three reasons: 1. NY-ESO-1 is considered one of the best targets for immunotherapy (Cheever et al., 2009 ). 2. There is preliminary clinical data in patients with both melanoma and synovial sarcoma (Robbins et al., 2011) .
3. There is good evidence of NY-ESO-1 antigen expression in oesophago-gastric cancers.
Success in this trial would indicate substantial activity of adoptive cellular therapy in a common epithelial malignancy that is di cult to treat by conventional means.
Eligible patients (N=28) were to be pre-treated with cyclophosphamide and Fludarabine. Cells would be transduced and expanded using standard protocol ( Figure 1 ). Patients would be given IL-2 after cell infusion. If there were 8 or more RECIST (Response Evaluation Criteria in Solid Tumours) de ned responses then the treatment is showing substantial activity in this hard to treat disease and is worthy of future development.
Trial II:
A Randomised Phase II Study in Metastatic Melanoma to Evaluate the E cacy of Optimised Cell Production Protocols
Engineered T-cells targeting NY-ESO-1 have already shown substantial activity in metastatic melanoma (Robbins et al 2011) and we aimed to test this further in a multi-centre phase II study comparing standard methods of cell production (Arm 1) with an optimised method of cell production (Arm 2). The optimised production was expected to produce cells with better engraftment capability and thereby greater clinical activity. The basic clinical aspects of the trial would be similar to Trial I. A total of 42 patients were to be randomly allocated to either one of these two treatment arms. The arm with the best RECIST de ned response rate would be used for future development.
The basic methods of cell production were to be similar in both trials as was the treatment the patient was to receive. However, in the arms with optimised cell production, the T-cells to be targeted for nucleic acid modi cation were to be pre-selected.
The project was built on strong on-going collaborations and previously successful EU pre-clinical applications (FP5 Chimeric Eurocell; FP6 ATTACK; FP7 ATTRACT (Initial Training Network)). The consortium brings together excellent clinical centres, key established industrial companies in the cell therapy eld, an SME with key patents in the eld and two service SMEs who aim to provide cell therapy as a service for patients. The project is coordinated by Professor Robert Hawkins (University of Manchester).
WP2: Cell Production
WP2 focused on GMP compliant cell production processes for both clinical trials including freezing of cells for use in multi-centre trials. We also aimed to develop a novel automated system for cell production; which would facilitate future larger scale use and testing of adoptive engineered T-cell therapy.
WP3: Laboratory Monitoring
WP3 was concerned with assay standardisation and laboratory monitoring of the two clinical trials with the additional aim of determining markers of therapeutic bene t and potential predictive markers of response.
Project Results:
WP1 Clinical Trials
Building on encouraging clinical results using T-cells to target NY-ESO-1 in melanoma, synovial sarcoma and myeloma, the consortium were to undertake two ground breaking Phase II trials The trial opened to recruitment in September 2014 and 39 patients were pre-screened for HLA status and NY-ESO-1 positive tumours. To date, two patients have been treated in the trial, one of whom passed away 46 days after initial treatment. The underlying cause of death was investigated by the ATTACK consortium and during the period of investigation, the Christie NHS Foundation Trust suspended enrolment in the trial.
The conclusions of the investigation were that the NY-ESO therapy was unlikely to have directly caused the bone marrow failure seen in the applicable patient through on-target toxicity or mispairing. The information was presented to the IDMC (independent data monitoring committee) in February 2016 and following review of the results, recommended that recruitment could resume once agreed changes to the protocol were in place. These included improving safety pro le by reducing the chemotherapy (to 3 days of cyclophosphamide and udarabine at a lower dose), omitting the IL2 and clarifying details within the protocol regarding the management of toxicity.
Protocol amendments were underway when noti cation was received that the European Union was to terminate funding of the trial due to the delays seen in the progress of the ATTACK program. Notice of intent to terminate was received by the project co-ordinator on 13th May 2016. Termination of funding became effective on 26th June 2016.
Trial I documentation has now been drawn up in preparation for submission to the regulatory authorities if appropriate funding can be secured following withdrawal of EU support. At the time of receipt of project termination noti cation, Trial II was in set-up phase and ready for submission to the regulatory authorities pending updated IMPD (Investigational Medicinal Product Dossier) and IB (Investigational Brochure).
After much discussion, the Consortium regretfully concluded that it was not feasible to perform the second trial that was originally planned. Although the issue of cell selection and methods of cell growth remain important and the trial is technically feasible, the Consortium did not feel it would be possible to recruit enough melanoma patients in a reasonable timescale because of other recent new therapies and current large numbers of competing trials. Other possible target diseases were discussed -the only one that is NY-ESO1 positive and su ciently common to recruit to a randomised phase II study in a timely manner is oesophago-gastric cancer and until we know the outcome of Trial I the consortium felt that this would not be appropriate.
WP2 GMP Validation and Process Development
WP2 had the following objectives:
1. The manufacture of NY-ESO-1 T-cells using pre-quali ed GMP (Good Manufacturing Practice) compliant bioprocessing procedures in Licensed EU manufacturing facilities, providing individual cryopreserved NY-ESO-1 speci c autologous T-cell products for the treatment of patients across the consortium of clinical treatment facilities 2. Development of an automated process for cell selection, activation and transduction based on the MILTENYI Prodigy System which will potentially streamline the manufacturing steps during the most labour intensive and process critical procedures and ultimately provide a simpli ed manufacturing process whilst maintaining an equivalent nal product.
Main activities and results:
The two production sites in this consortium are CTL and AmBTU.
CTL successfully validated the NY-ESO-1 speci c T-cell manufacturing process once agreements with ADAPTIM for cell manufacturing and virus supply were nalised. Trial I opened to recruitment in 2014. Four batches of cells have been manufactured.
CTL has provided information for amendments to the IMPD and IB for MHRA submission and is ready for new batches to be manufactured, but is awaiting approval of Trial I (ATTACK-OG) to re-open before further batches can be manufactured.
AmBTU is awaiting lentiviral vector from ADPTIM to allow validation of the manufacturing process.
As part of the development of the second arm of Trial II, CTL and MILTENYI have performed development work resulting in 2 successful engineering batches using CD62L selection, IL-7 & IL-15 and TRANSACT activation to produce Naïve/Central memory enriched NY-ESO-1 T-cells (NCM-NY-ESO-1 T-cells).
CTL along with AmBTU and ADAPTIM have developed GMP assays. CTL has performed additional GMP assays of nal products to provide stability data. The stability study assessed viability and gene expression of GMP manufactured products with matched cryobags and vials stored up to 9 months and vials form the initial validation study with stability data >2 years. In all cases, the bags and vials met the required release criteria demonstrating good long term product stability.
MILTENYI has completed the development of a fully integrated process that allows performance of clinical-grade T-cell selection from blood products, activation of the enriched T-cells and gene-modi cation via viral vector constructs. Robustness of the automated process using patient material has been veri ed. Some efforts are still remaining for nalization of the programing of the process (especially protocol generation for batch recording), documentation and de nition of QC and IPC tests that are an obligatory part of clinical manufacturing and will have to be completed outside of the project.
Detailed results/achievements
The manufacture of NY-ESO-1 speci c T-cells using pre-quali ed GMP compliant bioprocessing procedures in Licensed EU manufacturing facilities
During the project CTL implemented an adaptable gene engineered T-cell manufacturing process enabling the incorporation of novel technological improvements in a eld which is rapidly developing, ultimately allowing improvements in product quality and reducing manufacturing risk. CTL developed this process and Quality Control methods as part of the engineering batches leading to 3 validation runs, building on work carried out in advance of the project. The validation and QC data was incorporated into the IMPD, CTL developed, and was reviewed and approved by the MHRA as part of the Christie Clinical Trial Application which was approved in June 2013. Once the trial was opened by the Christie in Sep 2014 this resulted in the manufacture of 4 trial batches of which two where infused as part of Trial 1 prior to the trial being put on hold.
Prior to the trial being put on hold, a technology transfer process was underway between CTL and AmBTU enabling the proposed production process and Quality Control of NY-ESO-1 speci c T-cells to be transferred from CTL to AmBTU. This work would ultimately enable multicentre manufacture of NYESO-1 T-cells. The lack of available NY-ESO-1 TCR virus held up process validation at the AmBTU site as well as submission of an update to the IMPD to add AmBTU as an additional manufacturer of NY-ESO-1 T-cells.
The process for the second arm of Trial II was developed through two successful engineering batches and was held up after 3 validation runs which subsequently identi ed stability issues with the new activation reagent called TransAct. While MILTENYI had resolved the stability issue the validation was not completed due to both the Trial 1 hold and ultimately the programme hold.
In summary the work on tasks and deliverables related to the development and validation of the manufacturing process for Trial I were complete, with 4 batches successfully produced for patients within Trial I. The consortium had planned to complete Trial I, with some modi cations, following review of patient data from the rst two patients treated and the clinical protocol. Development and validation of the manufacturing process for Trial II was also largely complete. The legacy of the work on the manufacturing process and assays completed within the ATTACK project will enable the investigation of NY-ESO-1 in Oesophageal-gastric cancer to continue.
The development of an automated process for cell selection, activation and transduction based on the MILTENYI Prodigy system
The development of an automated process for cell selection, activation and transduction based on the MILTENYI Prodigy System can potentially streamline the manufacturing steps during the most labour intensive and process critical procedures and ultimately provide a simpli ed and therefore more reliable manufacturing process whilst maintaining an equivalent nal product.
To assess the impact of current and novel activation systems for potency, expansion, phenotype and transcriptome to identify impact of activation on cell characteristics and function we set up T-cell isolation, -stimulation and -transduction processes from frozen leukapheresis.
Given the published data showing that naïve and central memory T-cells are preferential subsets for adoptive T-cell therapy, we focused on the isolation of CD62L positive cells (containing the indicated T-cell subsets). In order to further automated process steps of the manufacturing of gene-engineered T-cells we also developed a novel soluble activation reagent that can be sterile ltered and biodegradable making it more suitable for automation. We worked on optimized culture conditions as well as dedicated tubing set.
After having developed stand-alone processes for the selection, activation and transduction of T-cells, MILTENYI developed a program
integrating T-cell selection from blood products, activation of the enriched T-cells and gene-modi cation via lentiviral vector in a single device platform. The transduced T-cells can be further expanded for up to 14 days in the Prodigy tubing set. We also developed one dedicated tubing set allowing for the GMP compliant manufacturing of gene-modi ed T cells in a single use, closed system. Currently the process gives robust results with cells from healthy donors. Further work is required to verify robustness of the automated process using patient material (and potentially implement adaptations if required).
With regard to the development of an automated process for cell selection, activation and transduction and assess comparability of activation methods, all reagents meant to be implemented in the automated clinical manufacturing process of improved gene-modi ed T-cells have been tested. Using clinical grade reagents, T-cells (from frozen leukapheresis) can be enriched for CD62L, are e ciently stimulated with a new activation reagent called TransAct and expanded in TexMACS medium, with IL-7 and IL-15. Optimal conditions
for T-cell stimulation, expansion and transduction have been assessed and determined. The work ow for the cell manufacturing has been streamlined for transfer to automation development in the prodigy platform. Novel tubing sets, more adapted to the work ow have been designed and produced.
CD62L T-cell selection by the Prodigy was assessed and compared to standard CliniMACS selection. Comparability testing between CliniMACS plus and Prodigy for CD62L enrichment has been performed successfully using a generic enrichment program available on the Prodigy platform. Successful enrichment of CD62L positive cells requires at least labelling and washing steps under cold conditions (using pre-cooled buffer to avoid shedding of CD62L). Therefore we adapted the speci c TCT software application regarding automated enrichment on the CliniMACS Prodigy under cold condition and generated comparative performance data for the semi-automated process on the CliniMACS Plus (manual cell preparation prior enrichment). In independent runs it was shown that using the CliniMACS Prodigy in combination with the optimized software application resulted in comparable or better purity and viability of target cells (CD62L+ among CD45+). To test reproducibility of the automated selection process on the CliniMACS Prodigy, enrichment of CD62L cells was then performed using different cell sources: either apheresis or buffy coats were used. Comparable results regarding purity and viability of target cells (CD62L+ among CD45+) were observed with differences in recovery resulting from the heterogeneity of the cell source. Therefore it is recommended to use apheresis product (focused on mononuclear cells) for the enrichment of CD62L+ cells. In summary, overall enrichment on the CliniMACS Prodigy enables an automated process that reduces user interactions to a minimum and increases usability for clinical compliance of cell manufacturing (e.g. no open steps required for cell preparation prior enrichment). Furthermore, the developed software application contains routines to handle possible failures, which will increase the success of target cell enrichment prior activation, transduction and expansion.
Generic formulation and harvest programs for gene-modi ed and expanded T-cells by the Prodigy have been generated and are functional. A formulation program has also been integrated in the fully automated process so that at the end of the manufacturing run, cells can be reformulated in the desired buffer. All cells are then harvested into a dedicated bag. Speci c dose preparation must be done manually.
The novel T-cell stimulatory reagent developed for its implementation in automated platforms has been compared to other stimulatory reagents available for clinical manufacturing. All reagents tested performed equally well and allowed e cient lentiviral and retroviral transduction of enriched T-cells. The Transact Reagent proved to be an e cient tool for the stimulation of enriched T-cells prior transduction especially in closed system thanks to the fact that it is compatible with sterile ltration. Protocols have been optimized e.g. ne-tuning of the time-point for lentiviral transduction to achieve su cient numbers of transduced T-cells in a maximum of 14 days manufacturing process. Furthermore we can demonstrate the removal of the TransAct Reagent from the cell preparations via simple washing is possible and a complex bead removal process as required for DynaBeads is no longer necessary. As a result, we focused on the automation of the TransAct stimulation on the CliniMACS Prodigy including the development of optimized protocols regarding stimulation dose or seeding cell density for the enriched CD62L population. In addition, safety aspects for the TransAct Reagent such as dose curve responses were addressed in vitro to ensure safety for clinical applications. Optimization of transduction after polyclonal T-cell stimulation includes determination of best dose and time-point for transduction. The TransAct stimulation reagent was compared with ExpAct or DynaBead (large bead based stimulatory reagents). For all polyclonal stimulation reagents best transduction e ciencies were reached if T-cells were transduced 24h after stimulation when using lentiviral vectors. The given example shows transduction e ciencies (% CD3+ GFP+) of the TransAct stimulated T-cells. Using optimized protocols for the fully-automated enrichment, stimulation and transduction on the CliniMACS Prodigy using the TransActs, we demonstrated that the manufacturing of gene-modi ed T-cells in the CliniMACS Prodigy resulted in better transduction e ciency compared to the manual process: higher frequency and intensity (MFI) of GFP+ cells were obtained in the CliniMACS Prodigy although cells were treated in a similar way for the small scale (manual process) or TCT (automated Prodigy process). Fully automated manufacture runs of gene-modi ed T-cells on the CliniMACS Prodigy indicated a comparable T-cell expansion for the full-automated (Prodigy) or manual (small-scale control) manufacturing process of CD62L selected, polyclonal stimulated (TransAct) and lentiviral transduced T-cells. In addition no differences in expansion of lentiviral modi ed or non-transduced T-cells were observed.
Note: We rst focused on the nalization of the lentiviral transduction protocol for the CliniMACS Prodigy before we started to adapt the protocol towards retroviral transduction. First feasibility runs indicate that the process we have developed for lentiviral transduction is suitable for the retroviral modi cation of selected T-cells although some changes and optimizations are required for the later.
Proof of principle that T-cells can be expanded in the Prodigy has been obtained. Expansion of CD62L enriched T-cells and optimization if the process was assessed. We were able to develop a robust manufacturing process for gene-modi ed T-cells on the CliniMACS Prodigy. Using this process we demonstrated that no differences in analysed parameter such as absolute cell counts, viability, T-cell phenotype, cell composition or function can be observed comparing transduced to non-transduced T-cells. Moreover, gene-modi ed Tcells manufactured using the TCT program on the Prodigy displayed convincing on target cytokine secretion and cytotoxicity. Also, we demonstrated that an expansion of CD62L selected cells in the CliniMACS Prodigy resulted in very high nal T-cell frequencies independent of genetic modi cation via lentiviral transduction. Furthermore we were able to develop an expansion protocol which enables manufacturing of a favourable central memory T-cell phenotype. Low frequencies of naïve and effector memory T-cells were determined after polyclonal stimulation, transduction and expansion of gene-modi ed T-cells. Robustness of manufacturing process of either transduced or non-transduced T-cells was demonstrated and nal cell counts with a total of up to 4x1E09 cells with high viability have been obtained.
In summary, we have developed novel strategies for the enrichment of effective T-cell subsets and optimized their activation, genemodi cation and expansion using newly co-developed soluble activation reagents, culture conditions (i.e. TexMACS medium + IL-7 and IL-15) and a dedicated closed single-use tubing set where all steps were integrated in a stepwise approach. We nally managed to develop a process on the CliniMACS Prodigy which integrates all essential steps for clinical-grade manufacturing of gene-modi ed Tcells. Automation of the manufacturing process is economically advantageous. This will contribute to the commercial realisation of adoptive cell transfer therapy. Moreover, user interactions and open handling steps for the T cell transduction process were reduced to a minimum to increase safety for each run making a complex procedure more reliable.
WP3 Laboratory Monitoring
WP3 "Laboratory Monitoring" focused on assay standardization and the e cient monitoring of the trial patients with the aim of determining key markers of therapeutic bene t and potential predictive markers of response. Within the objective following tasks were de ned: 1. The assessment of patient eligibility -HLA-A2 status and NY-ESO-1/LAGE expression; 2. Monitoring of immune status and persistence of infused NY-ESO-1 TCR engineered cells in patients
Analysis of general immune and T-cell speci c parameters in blood, tumour and pre-infused T-cells
The screening assays to assess positivity of expression of NY-ESO-1/LAGE-1 have been established and validated, as has the validation of ow cytometry (FCM) NY-ESO-1 tetramer staining assays and gene-modi ed T-cell speci c real-time PCR assays. The detailed protocols have been made available for participating clinical sites for local implementation.
Screening assays were applied on 39 patients, of which 4 were HLA-A2 positive and had a tumour that expressed NY-ESO-1 and/or LAGE-1. Presence of NY-ESO-1 TCR T-cells in patient blood was assessed in two treated patients using both FCM and qPCR methods.
Furthermore we have standardised the FCM research assays for quantitation and assessment of differentiation and activation status of NY-ESO-1 TCR T-cells prior to infusion and in patient blood, including markers for T-cell differentiation (i.e. CCR7, CD45RA, CD95); T cell function (e.g. CD107, IFNg, GrB) and exhaustion (e.g. PD1, LAG3, TIM3).
An archive for storage of patient material for future research has been established at EMC. Due to early termination of the project no data have been generated yet with respect to the additional research questions.
As per 26 June 2016 (termination of project): • Task 1: methods are de ned, validated (at UNIMAN/CHRIS) and made available for participating clinical sites for local implementation.
The IHC NY-ESO-1 and LAGE antigen screening of patient tumour specimen has only been active at UNIMAN/CHRIS. Thirty nine patients were screened, of which 4 were both HLA-0201A positive and NY-ESO-1 or LAGE-1, and two were actually treated.
•
Task 2: ow cytometry (FCM) and quantitative, real time polymerase chain reaction (qPCR) methods for detection of NY-ESO-1 TCR engineered T-cells in patient blood were based on validated methods in place at ADAPTIM and were validated and implemented at EMC (FCM) and UNIMAN (qPCR).
Blood samples of the 2 patients treated at CHRIS are processed for qPCR detection of NY-ESO-1 TCR T cells at UNIMAN/CHRIS. FCM detection of NY-ESO-1 TCR T cells in these patients was performed at ADAPTIM).
No products have been sent to EMC yet for detailed analysis of immune parameters.
•
Task 3: FCM and IHC method are de ned and implemented at EMC.
No products have been sent to EMC yet for detailed analysis of immune parameters
Detailed results/achievements
Assessment of patient eligibility
Enrolment onto each trial requires patients to be HLA-A2 positive and their tumour to be NY-ESO-1 and/or LAGE positive. HLA-A2 typing was recommended according standard local procedures.
The immunohistochemical (IHC) detection of NY-ESO-1 and LAGE antigen in tumour sections has been set up and validated, including indication of expression score, at UNIMAN/CHRIS.
Assay Development: 102 cases -comprising a mix of gastric and oesophageal specimens, both biopsy and excision specimens xed in neutral buffered formalin and processed into wax. 3-4 micron thick sections on charged slides prepared for immunohistochemistry. The monoclonal mouse anti-NY-ESO-1 (Invitrogen Cat No 35-6200) Clone E978, was used at a dilution of 1:200 (or 2.5 μg/ml) and the polyclonal rabbit anti-CTAG2 (LAGE) (Biorbyt Cat No orb101530) used at 1:300 (or 1.66μg/ml). Sections of normal testis were used as positive control for both LAGE and NY-ESO-1. Following routine dewaxing and rehydration protocols, antigens for NY-ESO-1 and LAGE (CTAG2), were retrieved using heat mediated antigen retrieval (HMAR), pH 9.0 Leica Bond epitope retrieval solution for NY-ESO-1 and pH 6.0 Citrate buffer for LAGE. Antibody binding was then visualised using Dako EnVision detection kit (Dako, K5007) according to the manufacturer's recommendations. Other detection systems were evaluated but were found to be suboptimal (Ventana Ultra View, Leica Bond Polymer detection kit).
Interpretation: Of the 102 cases employed in the detection study, 97 were evaluable for NY-ESO-1 and 91 for LAGE (Table 1) . Failures were due to inability to repeat (no spare sections), atypical staining or disagreement between two independent scorers. Staining was judged to be negative (score 0), weak (score 1), moderate (score 2), or strong (score3). In cases where interpretation was mixed, an average score was given (for e.g. weak/ moderate score = 1.5).
Per July 2014 the detailed protocol was distributed to participating clinical sites for local implementation (EMC, CHU NKI-AVL, and OSR). Local implementation at clinical sites included veri cation and interpretation of staining by a dedicated pathologist at CHRIS.
Conclusion: The IHC detection of NY-ESO-1 and LAGE antigen in tumour sections has been set up and validated, including indication of expression score. Distribution and mutual expression of both NY-ESO-1 and LAGE are documented. The detailed protocol has been put available for participating clinical sites for local implementation.
The IHC NY-ESO-1 and LAGE antigen screening of patient tumour specimen has only been active at CHRIS.
Peripheral persistence of gene-modi ed T-cells
Peripheral persistence of gene-modi ed T-cells was assessed by both FCM (EMC) and qPCR (UNIMAN) on processed and stored peripheral blood mononuclear T-cells (PBMC). Methods for collection, processing and storing PBMC for these assays were de ned and implemented at UNIMAN and EMC, and will be communicated to the other participating clinical sites. Standing Operating Procedure Quanti cation and activation status of immune subsets from PBMC FCM panel for assessment of activation status of immune subsets of PBMC was realized and implemented at EMC, including FCM quantitation and assessment of differentiation and activation status of NY-ESO-1 TCR T-cells prior to infusion and in patient blood was validated on site on 1) fresh peripheral whole blood samples; 2) freshly isolated PBMC and 3) cryopreserved and thawed PBMC. These assays have been set up using different panels to de ne distinct T-cell subpopulations, including markers for T-cell differentiation (i.e. CCR7, CD45RA, CD95); T-cell function (e.g. CD107, IFNg, GrB) and exhaustion (e.g. PD1, LAG3, TIM3).
Assessment of anti-gene modi ed T-cell immune responses
Method will be based on the method reported for anti-CAIX CAR modi ed T-cell immune responses (Lamers et al, Blood, 2011, 117, p72-82) . There have been no activities yet to this task. Potential Impact: Potential Impact
The ATTACK clinical trial consortium builds on results from the EU FP6 ATTACK pre-clinical project and EU FP7 ATTRACT training network. Adoptive cell therapy with engineered T-cells is a promising emerging technology with clinical application in the area of nucleic acid delivery for therapeutic purposes.
Before termination of the project, the potential impact of ATTACK was expected to be on several levels, with the most signi cant impacts being seen in the following area:
Adoptive Cell Therapy Clinical Trials Success in these trials would enable the ATTACK members and others to carry out larger trials and potentially lead to an approved treatment for multiple cancer types.
The trials could extend evidence of activity to a common epithelial cancer and thereby facilitate testing of the construct in other epithelial cancer which can express NY-ESO-1
The trials would provide data in melanoma where there is already preliminary evidence of extraordinary activity.
Success in these trials would con rm activity in a multi-centre setting which is important as many previous trials have largely been single institutional studies. This would stimulate interest in exploring other TCR and CAR targets.
Clinical Trials Management
Manchester Academic Health Science Centre -Trials Coordination Unit (MAHSC-CTU) has previous experience in managing cell therapy trials, having managed a single centre, CAR T-cell trial and a single centre, TIL trial, both delivered at The Christie NHS Foundation Trust from 2006-2016. However, as a multi-centre and European adoptive T-cell trial, the ATTACK program has enabled each department within MAHSC-CTU to build on this pre-existing trial management expertise.
All departments within the trials coordination unit (data management, statistics, project management, monitoring) have now undergone further training and gained greater experience in setting up and managing complex ATMP trials. As a result, the procedures and processes used within the unit have been improved. ATMP management systems have been re ned to improve ATMP handling logistics and traceability. Safety reporting procedures have been developed to expedite the reporting serious events related to the IMP to the relevant committees.
As an integral member of the consortium, the unit has been able to establish good working relationships between both the commercial and non-commercial partners. These relationships will ensure that the expertise within the unit will be utilised in future trials of this nature.
NY-ESO-1 TCR
A key aim of the project as a whole is to see available a licenced engineered T-cell therapy. ADAPTIM has the capability to take this treatment forward commercially.
The NY-ESO TCR therapeutic used in the ATTACK study targets the NY-ESO-1 peptide which is present in multiple cancer types. In addition to the use of the NY-ESO therapeutic used to treat esophageal patients in the ATTACK study, the same therapeutic TCR is used within Adaptimmune's NY-ESO SPEAR T-cell which is currently in multi-indication trials in the United States. Pilot studies are ongoing in synovial sarcoma, melanoma, multiple myeloma, non-small cell lung cancer ("NSCLC") and ovarian indications and a trial in myxoid round cell lyposarcoma is due to start in late 2016 and early 2017. The trials are ongoing in both solid tumours and hematologic cancer types, and in cancers where survival rates for patients can be very limited. Patients that are being treated in the NY-ESO SPEAR T-cell trials or in the ATTACK study often have limited or no other options for treatment. Adaptimmune's NY-ESO SPEAR T-cell therapies have already shown preliminary evidence of tumor reduction in patients and also show a promising risk/bene t pro le. The ATTACK study is the rst study in which an NY-ESO TCR therapeutic has been evaluated for the treatment of patients with advanced gastro-esophageal cancer, another solid tumour.
Cell Processing -Process Development
The successfully developed production protocol used in the ATTACK consortium is of great value for society, contributing to the availability of T-cell therapy for European cancer patients. It can be used in future clinical trials using T-cells modi ed with other T-Cell Receptors (TCRs) or Chimeric Antigen Receptors (CARs). The tumor types for which T-cell therapy can be useful are nowadays numerous and expanding (e.g. solid tumors like melanoma, NSLC or ovarian cancer and hematological disorders like AML and CML).
Cell Processing -Selection Technology
Successful testing of the optimised method of cell production in trial II, developed by MILTENYI, could open up large markets for this product as the approach could be established as the new international standard.
Cell Processing -The development of an automated process for cell selection, activation and transduction based on the MILTENYI Prodigy system Automation in conjunction with comprehensive protocols leads to simpli cation and therefore to a better access of a therapeutic approach while saving time and costs.
Within ATTACK integrated processes were re ned to provide results in a shorter period of time and automation reduced manual handling steps. As the CliniMACS Prodigy enables cell processing in a closed system, the clean room requirements will be reduced in comparison to processes with open handling steps, which will also positively impact manufacturing costs signi cantly. Thereby, reduced personnel costs and expenses for GMP laboratories will maximize access to this therapeutic approach otherwise available only in few specialized clinical centers worldwide.
Facilitating access to such cell therapy technology is ultimately meant to meet the growing need and demand of patients. Automation with the CliniMACS Prodigy will allow for scale-up of manufacturing processes for commercial use, e.g. when hundreds to thousands of cell therapeutic doses per year are required to perform phase II/III clinical trials with the goal of FDA approval.
To further support such dissemination, technological improvements made within ATTACK were undertaken with cost reduction in mind;
as an important success factor for highly individual cellular therapies will be cost, which has to be compatible with health systems.
This project allowed us to address all the fundamental steps required to shift a complex highly manual process towards a robust and fully automated manufacturing of gene-engineered T-cells on a single dedicated platform, the CliniMACS Prodigy.
Biotechnology Industry
The inclusion of a major industrial partner focussed on cell selection technology, along with two SME's who focus on the delivery of cell therapy, as well as major cancer centres with expertise in the eld will enhance European expertise and competitiveness in an important emerging market. The research will thus support the European biotechnology industry especially the SME's in this nascent eld and ensure the clinical potential is rapidly developed building on excellent scienti c expertise in this eld in Europe.
Gender Dimensions
Cancer is a common disease that affects both men and women. Our primary targets covered tumours that are common in both men and women. In general, both men and women are keen to take part in this form of research. Whilst we did not anticipate any gender bias, this was monitored. Of the thirty-nine patients pre-screened for HLA status and NY-ESO-1 positive tumours, 28% (11/39) were female.
All of the partner of ATTACK and their legal a liations work towards gender equality in recruitment. An ATTACK Gender Equality and Action Plan has been developed. This charter sits in a national, European and international context in order to promote good working practice for both men and women in an academic environment. The ATTACK consortium has set out different objectives to meet the gender action plan and improve gender equality within the eld of adoptive cell therapy:
• all of the ATTACK partners and their legal a liations work towards gender equality in recruitment and promote gender equality awareness The structure of the website is designed in a clear and consistent way so that visitors and users can easily navigate around the site.
Public Section
This area provides an insight into the project background in lay terms; details of consortium members and contact points, description of the ATTACK clinical trials and aims of the research activities.
Public queries can be sent via emails to the Project managers. This will then be redirected to appropriate clinical personnel if the matter pertains to a clinical matter or contact details of suitable cancer help organisations can be distributed.
Members Area
A secure password protected portal has been initialised from the ATTACK website folders for internal access. A link on the menu bar to the members section of the ATTACK website is located on the home page of the website
The intranet ts the following purposes: to convey information and archiving of essential documents for the consortium, the project scienti c members to nd agendas, minutes of meetings, project projections, quarterly WP progress reports and other resources. This allows the ow of emails directed to the Consortium to be sized down and to be minimised.
Publications
All of the ATTACK personnel have an excellent publication track record and we anticipated that as the project progressed, there would be an increase in joint publications by partners as well as continued high-quality publications by individual groups. During the course of the project, 15 ATTACK related papers have been published by Consortium members.
Presentations
As highlighted, wide dissemination is important for maximum impact. The ATTACK project has been presented at over 100 EU, national and international meetings and conferences, in the elds of immunology, cancer and gene therapy.
Meetings
An important dissemination achievement has been the successful 4th Cellular Therapy of Cancer Symposium which was held in London in March 2013. It was organised by The Society for Cellular Therapy of Cancer, founded by members of the European Commission Framework 6 funded ATTACK Consortium and the European Commission funded Framework 7 consortiums of ATTACK and ATTRACT. The goal of the symposium is to bring together world leaders in basic and translational immunology to present research concepts and clinical studies relevant to the development to the development of T-cell therapy of cancer. The programme included an outstanding group of speakers in cellular therapy research. The meeting highlighted the fast pace at which this eld is currently moving and the need for a further understanding of the cellular and molecular basis of the interplay between tumours and redirected immune cells. The symposia also underscored the importance for strong international collaboration, favoured by EU-like consortia and for standardized GMP procedures and immune-monitoring protocols.
Co-operation with other grants/programmes
There are many valuable partnerships between industry and the academic institutions participating in the project. ATTACK fosters these partnerships, which in turn stimulates signi cant advancement and collaborative activity both now and into the future.
For example, in May 2014, ADAPTIM entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK -a British company) for the development and commercialisation of its lead clinical cancer programme NY-ESO-1. Under the terms of the agreement, ADAPTIM will co-develop its NY-ESO-1 clinical programme and associated manufacturing optimisation work together with GSK. All e cacy and safety data from trials involving ADAPTIM's NY-ESO-1 T-cell receptors, including data from ATTACK trials, will contribute to the clinical proof of concept to enable GSK to continue development and commercialisation of this therapy.
Other productive ATTACK collaborations are highlighted below:
ATTACK This project builds upon previous EU funded pre-clinical projects (ATTACK FP6 and ATTRACT FP7) and comprises a multidisciplinary and translational research group with wide-ranging, relevant expertise. Located across 6 countries in the EU, there are 8 hospital sites, 2 cell manufacturing sites, 6 Universities and 4 companies involved in the project.
